This work aimed to evaluate the activity of a
lipid transfer protein isolated from Morinda citrifolia L. seeds, McLTP1, on the development of intestinal
mucositis following
irinotecan administration. McLTP1 (0.5, 2, and 8 mg/kg, i.v.) was injected into mice 1h before
irinotecan administration (75 mg/kg, i.p.; 4 days), and then for additional 6 days. Seven days after the first dose of
irinotecan,
diarrhea was assessed, and the intestine was removed for histological evaluation, assessment of intestinal over-contractility, measurement of
myeloperoxidase (MPO), proinflammatory
cytokines and
chemokine (IL-1, IL-6, and KC levels - a murine homolog of human IL-8
chemokine), analysis of
cyclooxygenase 2 (COX-2),
nuclear factor kappa B (NF-κB), and
nitric oxide synthase (iNOS) expression. At the two highest doses, McLTP1 administration decreased mortality and
diarrhea. McLTP1 (8 mg/kg, i.v.) significantly prevented
irinotecan-induced intestinal damage and led to a reduction in over-contractility of the intestinal muscle (p < 0.05). Moreover, McLTP1 decreased the MPO, IL-1β,
IL-6, and KC levels by 74.7%, 42%, 92.9%, and 95.9%, respectively. Also, the expression of COX-2, NF-κB, and iNOS was reduced. Our study provides a potential new therapeutic for preventing
irinotecan-induced
mucositis, improved clinical parameters, and reduced
inflammation.